Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 1092-1099

  Kim, Gi Ae ^a   Lee, Han Chu ^a   Kim, Min Ju ^a   Ha, Yeonjung ^a   Park, Eui Ju ^a   An, Jihyun ^a   Lee, Danbi ^a   Shim, Ju Hyun ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

HBV; Liver cancer; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; SERUM ALBUMIN; VIRUS DNA; HEPATITIS B(E) ANTIGEN;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; ASCITES; CANCER EPIDEMIOLOGY; CANCER RISK; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; JAUNDICE; KOREA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PORTAL HYPERTENSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTE COUNT; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B VIRUS; IMMUNOLOGY; INCIDENCE; LIVER NEOPLASMS; SEROLOGY; SOUTH KOREA; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SEROLOGIC TESTS; SEX FACTORS;

EID: 84927800027     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.11.031     Document Type: Article

References (29)

1. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
2. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
3. The Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B Clin Mol Hepatol 18 2012 109 162
4. C.M. Chu, and Y.F. Liaw Hepatitis B surface antigen seroclearance during chronic HBV infection Antivir Ther 15 2010 133 143
5. M.F. Yuen, D.K. Wong, J. Fung, P. Ip, D. But, and I. Hung HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 135 2008 1192 1199
6. Y. Arase, K. Ikeda, F. Suzuki, Y. Suzuki, S. Saitoh, and M. Kobayashi Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B Am J Med 119 2006 e9 e16
7. C.M. Chu, and Y.F. Liaw HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up Hepatology 45 2007 1187 1192
8. R. Moucari, A. Korevaar, O. Lada, M. Martinot-Peignoux, N. Boyer, and V. Mackiewicz High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study J Hepatol 50 2009 1084 1092
9. Y.C. Chen, I.S. Sheen, C.M. Chu, and Y.F. Liaw Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection Gastroenterology 123 2002 1084 1089
10. J. Simonetti, L. Bulkow, B.J. McMahon, C. Homan, M. Snowball, and S. Negus Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus Hepatology 51 2010 1531 1537
11. G.A. Kim, Y.S. Lim, J. An, D. Lee, J.H. Shim, and K.M. Kim HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability Gut 63 2014 1325 1332
12. M.J. Tong, M.O. Nguyen, L.T. Tong, and L.M. Blatt Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen Clin Gastroenterol Hepatol 7 2009 889 893
13. M.F. Yuen, D.K. Wong, E. Sablon, E. Tse, I.O. Ng, and H.J. Yuan HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects Hepatology 39 2004 1694 1701
14. J.H. Kim, Y.S. Lee, H.J. Lee, E. Yoon, Y.K. Jung, and E.S. Jong HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma J Clin Gastroenterol 45 2011 64 68
15. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
16. European Association for the Study of the Liver EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
17. V.W. Wong, S.L. Chan, F. Mo, T.C. Chan, H.H. Loong, and G.L. Wong Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers J Clin Oncol 28 2010 1660 1665
18. M.W. Yu, H.C. Chang, Y.F. Liaw, S.M. Lin, S.D. Lee, and C.J. Liu Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives J Natl Cancer Inst 92 2000 1159 1164
19. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, and K. Cusi The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
20. H. Kim, Y.M. Jee, B.C. Song, J.W. Shin, S.H. Yang, and H.S. Mun Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea Intervirology 50 2007 52 57
21. J. Liu, H.I. Yang, M.H. Lee, S.N. Lu, C.L. Jen, and R. Batrla-Utermann Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma Gut 63 2014 1648 1657
22. K.A. McGlynn, and W.T. London The global epidemiology of hepatocellular carcinoma: present and future Clin Liver Dis 15 2011 223 243 vii-x
23. B.C. Yoo, J.W. Park, H.J. Kim, D.H. Lee, Y.J. Cha, and S.M. Park Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea J Hepatol 38 2003 98 103
24. S.H. Ahn, Y.N. Park, J.Y. Park, H.Y. Chang, J.M. Lee, and J.E. Shin Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance J Hepatol 42 2005 188 194
25. Y.F. Liaw, D.Y. Lin, T.J. Chen, and C.M. Chu Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study Liver 9 1989 235 241
26. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I.M. Jacobson Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
27. R.G. Gish, T.T. Chang, C.L. Lai, R. de Man, A. Gadano, and F. Poordad Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B J Viral Hepat 17 2010 16 22
28. J.Y. Cho, Y.H. Paik, W. Sohn, H.C. Cho, G.Y. Gwak, and M.S. Choi Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease Gut 63 2014 1943 1950
29. J. Foucher, E. Chanteloup, J. Vergniol, L. Castera, B. Le Bail, and X. Adhoute Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study Gut 55 2006 403 408